Press releases

Stockholm – November 17, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, has been published in the European Journal of Haematology, an international journal for communication of research in hematology. The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease

Stockholm – November 13, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12

Stockholm – November 13, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult to treat cancers, today announces that Henrik Bergentoft today takes office as the company´s new Chief Financial Officer

Stockholm – November 8, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2023

STOCKHOLM – November 1, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter 2023 at 08:00 CET on November 8. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 8 at 09:00 CET

Stockholm – October 20, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers today announces that the composition of the Nomination Committee has been established

STOCKHOLM — September 29, 2023 — Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed due to exercise of warrants under the company´s incentive program. Through the exercise of the warrants the number of outstanding shares and votes has increased by 70,967 from 94,529,110 to 94,600,077. The share capital has increased with SEK 7,886 from SEK 10,503,235 to SEK 10,511,120

Stockholm – September 28, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces its decision to opt to abandon the application process to allow Pepaxti access to earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM), a so-called type II variation. The decision follows an updated, comprehensive analysis of the current landscape for treatment of multiple myeloma and is made to optimize value for both patients and shareholders. The decision does not impact the company´s financial projections or the estimated market potential of Pepaxti negatively

Stockholm – September 26, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), a reimbursed price for Pepaxti has been agreed on in Germany. The negotiated reimbursed price in Germany, which will also guide negotiations in other European markets, is reflective of the innovation Pepaxti brings to the market, and in line with the company´s financial projections

Stockholm — September 14, 2023 — Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides’ application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision